Compare Amphastar Pharmaceuticals Inc (AMPH) vs Carparts.Com Inc (PRTS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

PRTS trades at $5.87, down 1.92% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $50.44 million in 2025, though recent quarters have beaten EPS estimates. A recent reverse stock split and new credit facility aim to stabilize operations amid declining revenue trends from $676 million in 2023 to $548 million in 2025.

The outlook remains challenging with persistent losses and negative cash flow, but analyst consensus is positive with 60% buy ratings. Key risks include sustained unprofitability and competitive pressures, while potential upside hinges on cost control and execution of strategic initiatives to return to growth.